Schiaffino Simone, Massone Elena, Gristina Licia, Fregatti Piero, Rescinito Giuseppe, Villa Alessandro, Friedman Daniele, Calabrese Massimo
1 Department of Radiology, University of Genoa , Genoa , Italy.
2 Department of Surgery, Policlinico San Martino , Genoa , Italy.
Br J Radiol. 2018 May;91(1085):20180003. doi: 10.1259/bjr.20180003. Epub 2018 Feb 23.
Atypical ductal hyperplasia (ADH) is a proliferative lesion associated with a variable increased risk of breast malignancy, but the management of the patients is still not completely defined, with mandatory surgical excision in most cases. To report the results of the conservative management with mammographic checks of patients with ADH diagnosed by vacuum assisted breast biopsy (VAB), without residual calcifications.
The authors accessed the institutional database of radiological, surgical and pathological anatomy. Inclusion criteria were: ADH diagnosed by VAB on a single group of microcalcifications, without residual post-procedure; follow-up at least of 12 months. Exclusion criteria were the presence of personal history of breast cancer or other high-risk lesions; association with other synchronous lesions, both more and less advanced proliferative lesions.
The 65 included patients were all females, with age range of 40-79 years (mean 54 years). The maximum diameter range of the groups of microcalcifications was 4-11 mm (mean 6.2 mm), all classified as BI-RADS 4b (Breast Imaging Reporting and Data System 4b) and defined as fine pleomorphic in 29 cases (45%) or amorphous in 36 cases (55%). The range of follow-up length was 12-156 months (mean 67 months). Only one patients developed new microcalcifications, in the same breast, 48 months after and 15 mm from the first VAB, interpreted as low-grade ductal carcinoma in situ (DCIS) at surgical excision.
These results could justify the conservative management, in a selected group of patients, being the malignancy rate lower than 2%, considered in the literature as the "probably benign" definition. Advances in knowledge: Increasing the length of follow-up of selected patients conservatively managed can improve the management of ADH cases.
不典型导管增生(ADH)是一种与乳腺癌风险不同程度增加相关的增殖性病变,但对患者的管理仍未完全明确,大多数情况下需进行手术切除。报告经真空辅助乳腺活检(VAB)诊断为ADH且无残留钙化的患者通过乳腺钼靶检查进行保守治疗的结果。
作者查阅了放射学、外科学和病理解剖学的机构数据库。纳入标准为:经VAB在一组微钙化灶上诊断为ADH,术后无残留;随访至少12个月。排除标准为有乳腺癌个人史或其他高危病变;与其他同步病变相关,包括更高级别和较低级别增殖性病变。
纳入的65例患者均为女性,年龄范围40 - 79岁(平均54岁)。微钙化灶组的最大直径范围为4 - 11毫米(平均6.2毫米),均分类为乳腺影像报告和数据系统(BI-RADS)4b级,其中29例(45%)为细多形性,36例(55%)为无定形。随访时间范围为12 - 156个月(平均67个月)。仅1例患者在首次VAB后48个月,距首次VAB 15毫米处同侧乳房出现新的微钙化灶,手术切除时被解释为低级别导管原位癌(DCIS)。
这些结果可以证明在特定患者群体中进行保守治疗是合理的,因为恶性率低于2%,在文献中被视为“可能良性”的定义。知识进展:延长对保守治疗的特定患者的随访时间可以改善ADH病例的管理。